You are here

Article info

Article menu
Review
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases

Authors

  • Michael Thiele Biology Research, OncoOne Research & Development GmbH, Vienna, Austria PubMed articlesGoogle scholar articles
  • Seamas C Donnelly Department of Medicine, Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland PubMed articlesGoogle scholar articles
  • Robert A Mitchell Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, Kentucky, USADepartment of Surgery, J.G. Brown Cancer Center, University of Louisville, Louisville, Kentucky, USADepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USADivision of Immunotherapy, Department of Surgery, University of Louisville, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles

Citation

Thiele M, Donnelly SC, Mitchell RA
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases
Journal for ImmunoTherapy of Cancer 2022;10:e005475. doi: 10.1136/jitc-2022-005475
Online issue publication 
September 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.